In addition, treatment of CNS tumor-bearing hosts with anti-CD25 mAb delayed the tumor growth and prolonged the survival, suggesting that CCR4+CD4+CD25+ Tregs play an important role in suppressing the immune response to CNS tumors (El Andaloussi et al., 2006). This evidence concerns the gene CCR4 and neoplasm.